Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioFactura has secured a US patent for its StableFast Biomanufacturing Platform, allowing 32 claims which encompassed composition of matter, methods, commercial kits, and media formulations.
Subscribe to our email newsletter
The system is marketed to companies developing biopharmaceuticals including novel compounds and biosimilars with an emphasis on therapeutic monoclonal antibodies.
BioFactura president and CEO Darryl Sampey said the company intends to make StableFast platform available to many clients in the private and government sectors who look forward for the development of lifesaving drugs.
StableFast was commercially launched in the earlier part of this year.